Review of Statistical Methodologies for Detecting Drug-Drug Interactions Using Spontaneous Reporting Systems.

Abstract

Concomitant use of multiple drugs for therapeutic purposes is known as “polypharmacy situations,” which has been recognized as an important social problem recently. In polypharmacy situations, each drug not only induces adverse events (AEs) but also increases the risk of AEs due to drug–drug interactions (DDIs). The proportion of AEs caused by DDIs is estimated to be around 30% of unexpected AEs. The randomized clinical trials in pre-marketing typically focus emphasis on the verification of single drug safety and efficacy rather than the surveys of DDI, and therefore, patients on multiple drugs are usually excluded. However, unlike pre-marketing randomized clinical trials, in clinical practice (= post marketing), many patients use multiple drugs. The spontaneous reporting system is one of the significant sources drug safety surveillance in post-marketing. Commonly, signals of potential drug-induced AEs detected from this source are validated in real-world settings. Recently, not only methodological studies on signal detection of “single” drug, but also on several methodological studies on signal detection of DDIs have been conducted. On the other hand, there are few articles that systematically summarize the statistical methodology for signal detection of DDIs. Therefore, this article reviews the studies on the latest statistical methodologies from classical methodologies for signal detection of DDIs using spontaneous reporting system. This article describes how to calculate for each detection method and the major findings from the published literatures about DDIs. Finally, this article presented several limitations related to the currently used methodologies for signal detection of DDIs and suggestions for further studies.